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Summary
Lymphoid neogenesis is traditionally viewed as a pre-programmed process
that promotes the formation of lymphoid organs during development.
Here, the spatial organization of T and B cells in lymph nodes and spleen
into discrete structures regulates antigen-specific responses and adaptive
immunity following immune challenge. However, lymphoid neogenesis is
also triggered by chronic or persistent inflammation. Here, ectopic (or ter-
tiary) lymphoid organs frequently develop in inflamed tissues as a
response to infection, auto-immunity, transplantation, cancer or environ-
mental irritants. Although these structures affect local immune responses,
the contribution of these lymphoid aggregates to the underlining pathol-
ogy are highly context dependent and can elicit either protective or delete-
rious outcomes. Here we review the cellular and molecular mechanisms
responsible for ectopic lymphoid neogenesis and consider the relevance of
these structures in human disease.
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Secondary and ectopic lymphoid organs
Secondary lymphoid organs (SLOs) are responsible for
immune homeostasis and the development of adaptive
immune responses to invading pathogens.1 Here, the
accumulation of foreign antigens within the highly orga-
nized cellular architecture of SLOs facilitates antigen pre-
sentation to T and B cells and the establishment of
adaptive immunity. Encapsulated SLOs form at predeter-
mined locations during embryonic development and
include the spleen and lymph nodes. Lymph nodes are
strategically located throughout the body to monitor self
and non-self antigens displayed by antigen-presenting
cells as they are trafficking from peripheral organs and
tissue. The spleen is also important for protection against
pathogens carried in the blood. SLOs also include the
non-encapsulated mucosal-associated lymphoid tissues
that feature at barrier surfaces and include Peyer’s
patches, tonsils, nasal-associated lymphoid tissue and
bronchus-associated lymphoid tissue (BALT). These latter
types of SLOs are found in the sub-mucosal epithelium
and are responsible for preserving tissue integrity at bar-
rier surfaces by ensuring the maintenance of immune tol-
erance against protective commensal microbiota and host
responses to pathogenic insult.2
To generate fast and efficacious anti-pathogen
responses, lymphoid organs have evolved to maximize
encounters between lymphocytes and antigen-loaded anti-
gen-presenting cells. Consequently, lymphoid organs share
a cellular organization that includes a germinal centre
comprising antibody secreting and proliferating B cells
together with follicular dendritic cells (DCs); a T-cell
zone including naive cells recruited from the blood; high
endothelial venules (HEV) for lymphocyte extravasation;
and a network of stromal cells that provide chemokines
and extracellular matrix for cellular migration and struc-
tural integrity.1,3
Inflammation is the consequence of our immunological
response to infection, autoimmunity, cancer, injury and
allograft transplantation.4 Appropriate control of inflam-
mation ensures competent host defence and is governed
by cellular communication between non-haematopoietic
stromal cells, tissue-resident leukocytes and infiltrating
immune cells.4–7 However, inappropriate control, for
example during autoimmunity, results in sustained
immune responses causing chronic inflammation. With-
out therapeutic intervention, over time this inflammation
drives clinical symptoms that culminate in tissue destruc-
tion and loss of function.8 Leukocyte infiltration is classi-
cally viewed as a random, diffuse accumulation of cells
within affected tissues. However, there is emerging appre-
ciation that during chronic inflammation, infiltrating
immune cells can form highly organized aggregates of
lymphoid cells that resemble SLOs. These ectopic
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lymphoid follicles (ELFs), also known as tertiary lym-
phoid structures, can propagate local antigen-specific
responses within tissues.9,10 Occasionally, these ELFs are
named according to their site of development (e.g. indu-
cible bronchus-associated lymphoid tissue; iBALT).
Whereas SLOs develop during ontogeny, ELFs are ‘in-
duced’ in response to an inflammatory insult within tar-
get tissues. This is particularly the case where there is a
perceived need for sustained leukocyte extravasation due
to the failure to clear antigen. Such responses often occur
at sites of infection, autoimmunity, cancer, allograft rejec-
tion or continued insult from environmental irritants.
Consequently, ELFs are ‘transient’ structures, and often
resolve upon successful antigen clearance. So what con-
trols the development of these structures in inflamed tis-
sues? While the molecular signatures associated with ELFs
resemble those involved in SLO formation, the develop-
ment or maintenance of ELFs in these sites is significantly
influenced by the nature of the local tissue microenviron-
ment. For example, various novel immune subsets have
recently been identified as inducers of ELF development
that are distinct from the lymphoid tissue inducer (LTi)
cells involved in secondary lymphoid organogenesis. The
discovery of these subsets now provides new opportuni-
ties and therapeutic strategies for targeting ELF-driven
pathologies with biological drugs.
Here we review the cellular and molecular regulators
that govern ELF development, their functional impor-
tance in disease and how ELFs impact the application of
biological drug interventions in chronic disease and can-
cers.
Cellular initiators of ectopic lymphoneogenesis
Given that only a proportion of patients suffering any
particular inflammatory condition will develop ELFs – for
example, approximately 40% of patients with rheumatoid
arthritis develop synovial ELFs11 – ectopic lymphoid neo-
genesis must be controlled by a specific set of inflamma-
tory signals. Likewise, as some tissues and tumours are
more permissive to ELF development than others, the tis-
sue microenvironment must contribute defined signals
that are conducive to lymphoid neogenesis. In this regard,
the development of ELFs mimics many of the mecha-
nisms underpinning the organogenesis of SLOs (for a
comprehensive review of SLO development see refs 1,
12). Here, initiation of SLO development centres on an
interaction at the lymph node anlagen between
haematopoietic derived CD4+ CD45+ CD3 LTi cells and
lymphoid tissue organizer (LTo) cells of mesenchymal
origin. Here, LTi cells accumulate in response to the local
expression of CXCL13, interleukin-7 (IL-7) and receptor
activator of nuclear factor-jB ligand (RANKL; also called
TNFSF11), owing to the cell surface expression of CXCR5
and the IL-7 receptor (also called CD127). In response to
IL-7 and RANKL, LTi cells secrete lymphotoxin (LT)
a1b2, which engages the LTb receptor (LTbR) expressed
on LTo cells. In turn, LTo cells release the homeostatic
chemokines CXCL13, CCL19 and CCL21 in order to
recruit haematopoietic cells and up-regulate the expres-
sion of the adhesion molecules vascular cell adhesion
molecule 1, intercellular adhesion molecule 1 and muco-
sal addressin cell adhesion molecule-1 to ensure lympho-
cyte retention during SLO development.13,14 LTo cells
also secrete vascular growth factor-C, fibroblast growth
factor-2 and hepatocyte growth factor, which promote
the development of the lymphatic vasculature and
HEVs.12,14 Stromal LTo cells also differentiate into stro-
mal cell lineages including follicular DCs, fibroblastic
reticular cells and marginal reticular cells, which populate
lymph nodes and contribute to SLO function.12,15,16
There is increasing evidence that immune cells
recruited to inflammatory lesions initiate ELF develop-
ment (Fig. 1). For example, IL-17-secreting CD4 T helper
(Th17) cells have been extensively linked with ELF devel-
opment in experimental models of chronic inflamma-
tion.17 Here, the development of iBALT as a consequence
of pulmonary inflammation was dependent on the Th17
signature cytokine IL-17, which caused an LTa-indepen-
dent induction of the lymphoid chemokine CXCL13.18
This demonstrates the ability of this effector T helper cell
to initiate ELF development. Notably, the adoptive trans-
fer of in vitro generated Th17 cells into mice is also suffi-
cient to drive ELF development in a model of multiple
sclerosis.19 The expression of the cell surface glycoprotein
podoplanin (also called gp38) by Th17 cells was required
for the development of these lymphoid follicles in the
central nervous system. Indeed, mice deficient in podo-
planin, or its receptor CLEC-2, display a defect in the
development and maintenance of lymph nodes.13,19,20
Our recent study of synovial ELF development in IL-27R-
deficient mice with inflammatory arthritis identified
podoplanin-expressing T cells within synovial lymphoid
aggregates and described IL-27 as a negative regulator of
podoplanin-expressing Th17 cells.21
Recently, other cytokines linked with the IL-17/Th17
cell axis have also been associated with control of lym-
phoid neogenesis (Fig. 2). For example, IL-23 is linked
with ectopic lymphoid neogenesis in rheumatoid arthri-
tis.22 Through control of lymphoid chemokine produc-
tion in epithelial and fibroblastic stromal cells, IL-22 also
drives lymphoid neogenesis in mice following salivary
gland cannulation with adenovirus.23 Podoplanin and IL-
17 have also been linked with ectopic lymphoneogenesis
in human diseases.21,24,25
It has recently emerged that Th17-type responses are
not solely restricted to conventional T helper cells. Adult
LTi cells, a group-3 innate lymphoid cell subset, bear
many of the features of Th17 cells, which suggests an
ancestral link between these cell types.26,27 Both cells
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express the transcriptional regulator retinoic acid recep-
tor-related orphan receptor c; are responsive to IL-23 and
aryl hydrocarbon receptor ligands; and can produce IL-
17, IL-22 and granulocyte–macrophage colony-stimulating
factor.28–30 Like Th17 and fetal LTi cells, innate lymphoid
cells have been linked with lymphoid organogenesis. The
adoptive transfer of adult CD4+ CD3 LTi cells into
Cxcr5/ mice induces the development of intestinal lym-
phoid tissues.31 Similarly, the increased availability of IL-
7 in transgenic mice has been associated with the LTi
cell-dependent development of additional Peyer’s patches,
caecal patches and de novo formation of ectopic lymphoid
organs.32 A recent study has also shown that IL-17
induces CXCL12 and iBALT development in response to
Pseudomonas aeruginosa infection, where the main source
of IL-17 was cd T cells (Tcd17 cells).33 The similarities in
effector characteristics between Th17, LTi cells and cd T
cells may therefore account for the ability of these popu-
lations to drive ELF development (Fig. 1).
T follicular helper (Tfh) cells promote B-cell activities
and support the generation of high-affinity antibodies at
germinal centres.34,35 Plasticity among effector T helper
cells may also contribute to ELF development. For exam-
ple, Th17 cells are linked with ELF development in the
central nervous system, lungs and inflamed joint tis-
sue.18,19,21 Interestingly, in the central nervous system
Th17 cells develop a ‘Tfh-like’ phenotype that may con-
tribute to ELF development and function.19 ELF develop-
ment during inflammatory arthritis is also linked with the
local expression of Th17 and Tfh effector cytokines and
transcription factors.21 Similarly, Th17 cells that home to
Peyer’s patches can acquire Tfh-like effector characteris-
tics that support antigen-specific IgA responses at germi-
nal centres.36 Here, Th17 cells recruited to the intestine
express podoplanin. Therefore, lineage plasticity may pro-
vide the ability for effector T cells to develop Tfh-like
properties that support the development, maintenance
and function of ELFs. Indeed, T helper cell plasticity is
not solely confined to Th17 cells, and both Th1 and Th2
cells retain the ability to acquire the IL-21, CXCR5, Bcl-6,
programmed cell death-1 and inducible T-cell co-stimula-
tor expression that are characteristic of Tfh cells
(Fig. 1).19,36–38 Therefore, other subsets beyond Th17 cells
may soon emerge as initiators of ELFs.
Inflammatory cells may substitute for LTi cells in ecto-
pic lymphoneogenesis, but there is increasing evidence that
stromal tissue cells also display LTo-like properties39–41. In
rheumatoid arthritis, synovial fibroblasts contribute to ELF
formation through the secretion of homeostatic chemoki-
nes such as CXCL13, CCL21 and CXCL12.5,23,42–44
Interestingly, synovial fibroblasts can also contribute to
other aspect of ELF activity, where they can produce
B-cell-activating factor and a proliferation-inducing
ligand (known as APRIL).45 These factors support
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Figure 1. Novel immune cell subsets implicated in the regulation of ectopic lymphoid follicles (ELFs). Novel innate and adaptive immune cell
subsets have recently been implicated in ELF regulation. These include the adult lymphoid tissue inducer (LTi) -like or innate lymphoid 3 cells,
interleukin-17 (IL-17) -producing cdT (Tcd17) cells, T helper type 17 (Th17) cells and follicular T helper (Tfh) cells. Here we highlight the simi-
larities in their phenotype including the cytokines involved in their development, proliferation and effector function, the receptors expressed on
the cell surface and the effector cytokines produced by these cells. Similarities in the effector characteristics of these cells may account for their
common ability to regulate ELF development or activity. TSLP, thymic stromal lymphopoietin; SCF, stem cell factor; GM-CSF, granulocyte–
macrophage colony-stimulating factor; TNF, tumour necrosis factor; PD-1, programmed cell death-1; ICOS, inducible T-cell co-stimulator.
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activation-induced cytidine deaminase (AID) expression,
which drives somatic hypermutation and antibody class-
switching in B cells.45 Here, it is important to understand
the relationship between the stromal tissue compartment
and the nature of the inflammatory infiltrate because ELFs
are not a universal feature of synovitis in inflammatory
arthritis and only occur in a certain cohort of patients.
Homeostatic chemokines in ELF development
The expression of homeostatic chemokines is increased in
tissues where ELFs have emerged in response to foreign
or auto antigens.1,9,10,12 Chemokines such as CXCL13,
CCL19, CCL21 and CXCL12 are involved not only in the
initiation of ELF development, but also in the mainte-
nance of the highly organized cellular architecture of
established ELFs and SLOs. Given that the early clustering
of LTi cells within the embryo is dependent on CXCL13,
and that CXCL13 is detected early in the developing
lymph nodes of LTa-deficient mice,46,47 this chemokine
represents a key initiator of lymphoid organogenesis that
functions upstream of LTbR signalling. At ELFs, CXCL13
and CCL21 regulate B-cell and T-cell infiltration and seg-
regation at ELFs.48–50 Similarly, chemokines CCL19 and
CXCL12 drive lymphocyte recruitment and the position-
ing of follicular DCs, B cells and plasma cells at germinal
centres.48 Here, an elegant cooperation between CXCL12
and CXCL13 directs the movement of B cells from the
dark zone into the light zone as they mature into anti-
body-secreting plasma cells.51 Hence homeostatic and cer-
tain inflammatory chemokines contribute to both the
initiation of ELF development, the cellular organization
required for their function as germinal centres.
In addition to their chemotactic properties, homeo-
static chemokines promote the secretion of LTa1b2 by B
cells and T cells, which establishes a feedback loop to per-
petuate lymphocyte recruitment and positional organiza-
tion.49,50,52 Interestingly mice lacking CXCL13, or its
receptor CXCR5, fail to develop peripheral lymph nodes,
underlining the importance of this chemokine in
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Figure 2. Novel cytokine regulators of ectopic lymphoid follicle (ELF) development and function. The formation of ELFs at sites of chronic
inflammation mirrors the pre-programmed development of conventional secondary lymphoid organs (SLOs). During secondary lymphoid
organogenesis, the cytokines interleukin-7 (IL-7), receptor activator of nuclear factor-jB ligand (RANKL) and lymphotoxin (LT) ab initiate the
chemokine-directed positive feedback loop that drives B-cell, T-cell and follicular dendritic cell (DC) recruitment during lymphoid neogenesis.
Recent studies have implicated novel T helper cell subsets as initiators of ELF formation. Given the role that cytokines play in the regulation of T
helper cell differentiation and effector function, a number of cytokines have now been linked with the control of ELFs. For example, cytokines
involved in the regulation of T helper type 17 (Th17) cell responses (IL-6, IL-21, IL-23, IL-27, IL-2, IL-22, IL-17)23,137,139,145,148,152 and follicular
T helper (Tfh) cell responses [IL-6, IL-21, Type I interferons (IFNs), IL-27, IL-2]137,139,146,147,150 are emerging as regulators of lymphoid neogene-
sis. Here we highlight cytokines that may positively (red) and negatively (blue) control ELFs based on their ability to regulate effector T-cell pop-
ulations involved in ELF development or function. These cytokines, as well as their downstream signalling pathways and transcription factors,
have the potential to serve as therapeutic targets in clinical conditions where ELFs feature.
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lymphoid organogenesis.50,52,53 Transgenic overexpression
of Cxcl13 in the pancreas induces the production of
LTa1b2 by B cells that is required for the development of
ELFs that feature T-cell and B-cell segregation with HEV
formation.49 CCL19 and CCL21 similarly drive the
expression of LTa1b2 on naive CD4 T helper cells.
48
Hence, homeostatic chemokines are an integral feature of
ELF development, organization and function. Neverthe-
less, there appears to be some hierarchy among these
chemokines in their ability to drive ectopic lymphoneoge-
nesis. For example, transgenic overexpression of Ccl21
promotes the development of larger lymphoid follicles
than those that emerge in response to Ccl19.48 Transgenic
Ccl21 expression also promotes the development of ELFs
that display higher cellular organization than Ccl19. Inter-
estingly, ectopic Cxcl12 expression induces ELFs that con-
tain few T cells but are enriched for follicular DCs, B
cells and plasma cells.48 Therefore, as well as determining
the size and degree of cellular organization within ELFs,
the relative expression of homeostatic chemokines at
inflammatory lesions will also determine the cellular com-
position of ELFs.
It is clear that some chronically inflamed tissues are
more permissive to ELF development than others. For
example, transgenic expression of Ccl21 in the pancreas
promotes ELFs that display T-cell and B-cell segregation,
HEV and stromal reticulum. However, this response is
context dependent and Ccl21 in the skin fails to initiate
lymphoneogenesis.54,55 Histological features of ELFs are
seen in various chronic inflammatory diseases and are
clinically observed in the lung, joint synovium, liver, thy-
mus, and salivary and thyroid glands (for a comprehen-
sive review of ELFs in human disease refer to Pitzalis
et al.10). Structurally mature ELFs are not, however, seen
in skin conditions despite local expression of Ccl21, which
suggests that the immune setting and the interaction of
the stromal compartment with resident and infiltrating
cells has to be conducive for ELF development to
occur.56,57 This may reflect differences in innate sensing
responses or a differential stromal response to chemoki-
nes and cytokines necessary for the initiation, expansion
and maintenance of tissue ELFs.
High endothelial venules at ELFs
The function of SLOs depends on HEV that express
peripheral node addressin and mucosal addressin cell
adhesion molecule, which regulate the entry of naive T
cells into the lymph node. Similarly, HEVs are also
observed in ELFs that develop in response to autoim-
mune disease, allograft rejection and cancers.41,58–64 How-
ever, HEVs also develop in tissues that do not feature
ELFs,65–67 which infers that HEV neogenesis occurs before
the recruitment of peripheral T and B cells and the emer-
gence of ELFs. In peripheral lymph nodes, LTbR
signalling in DCs and endothelial cells promotes HEV
formation and maturation.68,69 However, the mechanisms
responsible for HEV development in inflamed tissues are
less clear. In human breast cancer, HEVs correspond with
a heightened expression of LTb by mature DCs.66 Here,
high densities of HEVs are associated with a reduced fre-
quency of FoxP3+ regulatory T (Treg) cells. Similar data
have also been obtained in an experimental model of car-
cinogen-induced fibrosarcoma, where Treg cell depletion
caused reduced tumour growth and increased HEV for-
mation.65 Indeed, HEVs in solid tumours are regarded as
positive prognostic indicators and patients are often dis-
ease free for longer, show reduced evidence of tumour
metastasis and display improved survival rates.9,65–67,70 In
primary and metastatic tumours, HEVs are associated
with increased infiltration of naive, central memory and
activated T cells that display a Th1 effector pheno-
type.66,67,70 A high density of extra-tumoral and intra-
tumoral Th1 cells correspond with improved survival,71
where it is proposed that their local priming, possibly
within ELFs, promotes antigen-specific tumour
responses.72,73 In murine models of melanoma and lung
carcinoma, the development of lymph node-like vascula-
ture allows naive T-cell entry into tumours that delay
tumour outgrowth.74 Therefore modulation of HEV
development or function through targeting LTa1b2 to the
tumour or by inhibiting Treg activity may provide oppor-
tunities for novel immunotherapies.
ELFs as inductive sites for anti-pathogen immune
responses
Chronic bacterial and viral infections can trigger inflam-
mation that results in the development of ELFs (compre-
hensively reviewed elsewhere75,76). For example,
Helicobacter spp. and Mycobacterium tuberculosis bacteria,
as well as influenza and hepatitis C viruses, have been
linked with ELF development in mice and humans.77–84
Interestingly, ELF formation in response to infection fea-
tures at mucosal sites including lung, gastric and salivary
gland tissues.78,82,85 ELFs that develop in response to
microbiota are also important for maintaining intestinal
homeostasis.86 There is considerable evidence linking
ELFs with anti-microbial and viral immunity. For exam-
ple mice lacking spleen, lymph nodes and Peyer’s patches
mount robust B-cell and T-cell responses to influenza
virus at sites of iBALT formation.82 Notably, in the
absence of peripheral lymphoid organs, these mice toler-
ate higher virus doses than wild-type mice, suggesting
that the anti-viral response generated at iBALT is not
only protective but may also be less pathogenic than
those generated in the periphery. Mice were able to show
effective primary and memory responses to viral challenge
via ELFs, associated with the emergence of influenza-spe-
cific CD8 T cells and anti-influenza nucleoprotein-specific
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antibodies.81,82 Development of iBALT in response to
infection was again linked to CXCL13 and CCL21 expres-
sion locally,82 but was also dependent on CD11chi DCs.80
Here, DCs were required for the maintenance of iBALT,
and DC depletion resulted in the regression of the ELFs
resulting in a reduction in germinal centre reactions, the
number of class-switched plasma cells and anti-viral
serum antibodies.
Similar ELF-associated anti-pathogen responses are also
described for M. tuberculosis and murine cytomegalovirus
infection in mice. In pulmonary M. tuberculosis infection,
ELF development was associated with CXCL13, CCL21
and CCL19 expression and the recruitment of functional
CXCR5+ T cells.77,79 T cells expressing CXCR5 displayed
Tfh- and Th1-like effector characteristics and were impor-
tant for host survival, M. tuberculosis clearance, T-cell
localization within ELFs, and lymphoid follicle forma-
tion.79 In murine cytomegalovirus infection, lymphoid
follicles that form in the salivary glands participate as
inductive sites in oral mucosal immunity.85 Development
of these salivary follicles was accompanied by a local
expression of homeostatic chemokines and molecular
markers such as AID and IlCa (the non-excised rear-
ranged DNA of IgA class-switching), which regulate ger-
minal centre activities including somatic hypermutation
and class-switch recombination.85
Development of ELFs is therefore an integral part of
anti-microbial and anti-viral immunity. Although the reg-
ulation of these ELF-driven responses can occur indepen-
dent of SLOs, their presence in infected tissues supports
adaptive immunity and the activities of SLOs. In humans,
ELF involvement is often associated with persistent infec-
tions. Here, a failure to eradicate pathogens may lead to
aberrant adaptive immune responses at ELFs that, when
inappropriately controlled, drive the onset of tissue dam-
age and chronic inflammation and transition to autoim-
munity or cancer.
ELFs as regulators of anti-tumour immunity
Current cancer immunotherapies aim to enhance the
adaptive immune response to tumour antigens to over-
come the immunosuppressive microenvironment of the
tumour.87 In this context, it is therefore surprising that
ELFs arise in tumours at all. However, ELFs have been
described in numerous cancers including colorectal,60,88
rectal,89 breast,67,90,91 ovarian67,92 and germ cell93 cancers,
as well as melanoma,62,67,94 mucosal-associated lymphoid
tissue lymphoma39 and non-small cell lung carcinoma95,96
(NSCLC; see Dieu-Nosjean et al. for a comprehensive
review of ELFs in cancer9).
Structures resembling lymphoid follicles are reported at
all stages of cancer, including primary tumours and
metastases,97,98 and in tumours removed after chemother-
apy.9,96 A number of studies have reported a correlation
between the density of ELFs and the degree of T-cell and
B-cell infiltration in tumours.94–97 This is interesting,
given that the frequency of T-cells displaying Th1 and
cytotoxic effector characteristics are linked with improved
patient survival in cancer.9,71 Indeed, ELFs in melanoma
and NSCLC are associated with favourable patient out-
comes and represent prognostic indicators of disease pro-
gression.94,95 In lung tumour-associated ELFs, a high
proportion of mature DCs correlate with gene signatures
linked with Th1 cell activation and improved long-term
patient survival.97 Similar observations have been
reported for B-cell densities in NSCLC, where follicular B
cells correlate with long-term survival both in early-stage
disease and in advanced disease treated with chemother-
apy.96 Therefore, ELF development may facilitate the
recruitment of naive T and B cells from the peripheral
pool via HEVs and homeostatic chemokines. Once estab-
lished, T-cell and B-cell priming within ELFs may provide
a local source of antigen-specific effector cells to drive
anti-tumour immunity.
Of course it is also possible the ELFs develop as a conse-
quence of cancer-associated inflammation, and are simply
spectators of the inflammatory process rather than partici-
pants in tumour-specific immune responses. However, in
experimental mouse models, effective T-cell priming at
tumour-associated ELFs have been demonstrated, that
occur independently of SLOs.72,99 Similarly in human
NSCLC tumour-associated ELFs, the density of germinal
centre B cells correlates with the number of antibody-
secreting plasma cells specific for endogenous tumour-
associated antigens.96 A recent study has also shown that
Treg cells in lung adenocarcinoma suppress anti-tumour
responses within tumour-associated ELFs.100 These studies
support a role for ELFs as sentinels for the propagation of
adaptive immunity against cancer antigens. Immunothera-
pies that support the activities of ELFs therefore represent
promising anti-cancer treatments. These may include deliv-
ery of regulatory homeostatic chemokines and cytokines or
interventions that block Treg involvement at ELFs.65,100
ELFs as perpetuators of inflammation-driven
pathology
Ectopic lymphoid follicles are associated with various
autoimmune and chronic inflammatory diseases including
rheumatoid arthritis,11,101,102 Sj€ogren syndrome,103 multi-
ple sclerosis,104 experimental diabetes,105 atherosclero-
sis,106,107 inflammatory bowel disease108,109 and chronic
obstructive pulmonary disease110,111 (for a comprehensive
review of ELFs in autoimmunity see refs 10,76). In con-
trast to their roles in infection and cancer, ELFs in
chronic inflammatory diseases are primarily associated
with disease exacerbation.
Rheumatoid arthritis is an example of an autoimmune
disease where ELFs impact the course of disease and the
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response to therapy. In rheumatoid arthritis, synovitis is
classed into three distinct pathotypes based on cellular
and molecular signatures of inflammation – termed
pauci-immune (or fibroblast-rich disease), diffuse and fol-
licular.11,101 Synovial ELFs are a prominent feature of the
follicular form of synovitis and are described in approxi-
mately 30–50% of patients with rheumatoid arthri-
tis.11,43,102,112,113 Notably, ELFs are described at all stages
of the disease and include patients with early active dis-
ease who have not received biological agents, patents with
more progressive forms of rheumatoid arthritis, and those
that have already received biological intervention.43,112,113
Although the mechanisms contributing the development
of this form of pathology are largely unclear, ELFs in
rheumatoid arthritis are associated with heightened syn-
ovial expression of CXCL13, CCL21, CCL19 and
CXCL12, and cytokines LTa1b2 and IL-7.
21,44,114,115
Importantly, these structures correlate with disease sever-
ity and are associated with local T-cell priming and
autoantibody production.43,116–118 Plasma cells in
rheumatoid synovitis produce autoantibodies against
citrullinated protein/peptides (ACPA/anti-CCP).116 Using
an elegant human rheumatoid arthritis–severe combined
immunodeficient (HuRA–SCID) mouse chimera model,
Humby et al. demonstrate that the synovial microenvi-
ronment determines the functional maintenance of ELFs
and that control of this process is independent of further
leukocyte infiltration.116 In this context, grafted synovial
tissues containing ELFs continued to secrete ACPA and
express AID.116 Although ACPA is a prognostic marker of
rheumatoid arthritis in patients with early/undifferenti-
ated disease, detection of serum ACPA is not indicative
of ELF-associated synovitis.113 The presence of synovial
ELFs is however associated with severe synovitis and
patients with this form of disease remain challenging to
treat and display a poor response to anti-tumour necrosis
factor (anti-TNF) therapy.112,119 Here synovial IL-7 recep-
tor expression also predicts a negative response to anti-
TNF intervention.112 Although ELFs frequently correlate
with the degree of synovitis and the infiltration of T cells
and B cells,21,113 it is still unclear whether their presence
reflects increased clinical severity or more rapidly pro-
gressing forms of rheumatoid arthritis.113 Importantly,
ELFs have been linked to an inferior clinical response to
anti-TNF therapy.112 However, in patients with ELFs that
showed favourable responses to anti-TNF treatment,
regression of synovial ELFs correlated with improved clin-
ical outcome.112 Further studies are therefore required to
better define how ELFs relate to clinical severity and ther-
apeutic response to biological agents in rheumatoid
arthritis.
Ectopic lymphoid follicles often form in transplanted
human tissues where chronic inflammation is associated
with allograft rejection. Tissues derived from kidney
transplantation demonstrate that ELFs contribute to ger-
minal centre reactions, local B-cell maturation and
alloimmune responses (anti-HLA antibody generation).
Whereas these observations support a role for ELFs in
chronic terminal rejection,120 two studies suggest that
ELFs may actual elicit beneficial outcomes.121,122 These
findings in experimental models of kidney and cardiac
allografts emphasize that ELF development promotes the
recruitment of T cells and B cells displaying inhibitory or
regulatory phenotypes.121,122 Such activities would be pre-
dicted to suppress destructive alloimmune responses and
promote graft tolerance.
Although lymphoid neogenesis is typically associated
with exacerbation of chronic inflammatory processes, a
recent study demonstrates a protective role for ELFs in
atherosclerosis.107 ELFs develop in the aorta of aged
Apoe/ mice where they correlate with disease sever-
ity.123 These structures were typically located adjacent to
atherosclerotic plaques where they control immune cell
trafficking, antigen presentation and T-cell priming and
differentiation.107 Hence, aortic ELFs may play an impor-
tant role in establishing local T-cell immunity during age-
ing in atherosclerosis.
Concluding remarks and future perspectives on
the therapeutic targeting of ELFs
Based on the current literature it is envisaged that two
immunotherapeutic strategies are required to target ELFs.
In infection and cancer it would be desirable to bolster
the development and activity of ELFs to support antigen-
specific responses. In contrast, the neutralization of ELFs
in chronic inflammatory diseases and transplantation
would limit tissue damage and rejection. However, to
date the number of clinical studies targeting ELF-asso-
ciated pathology remains limited.
One potential strategy is to disrupt the spatial arrange-
ment of T and B cells in ELFs. In chronic renal allograft
rejection, B-cell depletion with rituximab (anti-CD20
monoclonal antibody) had a limited impact on the main-
tenance of ELFs and biological intervention promoted
expression of the B-cell survival factor, B-cell-activating
factor.124 In rheumatoid arthritis, patients with ELFs
show an inferior clinical response to anti-TNF therapy,
which typically targets macrophage and stromal cell
responses.112 Other licensed biological therapies including
IL-6 or IL-6 receptor-specific monoclonal antibodies (e.g.
tocilizumab), T-cell activation antagonists (e.g. abatacept)
and Janus kinase inhibitors (e.g. tofacitinib) are likely to
target pathways linked with ELF activity. However,
although effective in attenuating inflammatory processes
that reflect their broader modes of action, their efficacy
in controlling ELF activity are untested.10,125 Given their
prominent roles in lymphoid neogenesis, targeting LTab
(e.g. baminercept and pateclizumab) may prove effective
in blocking ELF activity. Although clinically untested for
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ELF-associated inflammation, targeting LTb has shown
promise in pre-clinical experimental models of dis-
ease.126–129 Similarly, CXCL13 blockade has shown some
promise in pre-clinical studies for the treatment of exper-
imental inflammatory arthritis, diabetes and Sj€ogren syn-
drome.130–132 Finally, given the role of IL-21 in
regulating Tfh cells and germinal centre reactions, a
monoclonal antibody against IL-21 (NNC0114-0006) is
currently in clinical trials for rheumatoid arthritis and
systemic lupus erythematosus. These trials follow encour-
aging evidence for amelioration of disease following
blockade of IL-21 signalling in experimental inflamma-
tory arthritis, systemic lupus erythematosus and graft-ver-
sus-host disease.133–135
In cancer, promoting ELF activity may support the
development of protective antigen-specific responses. As
such, targeting cytokines such as LTab to tumours may
have therapeutic potential as demonstrated in experimen-
tal melanoma.72,99 Recent studies also suggest that inhibi-
tion of Treg cell activities could promote endogenous
anti-tumour immune responses at ELFs.65,100 In support
of such approaches, a suppressive role for Treg cells in
iBALT development has also recently been reported.136
In recent years, we have seen an increasing appreciation
for the importance of ELFs as inducible sites within tis-
sues for generating immune responses to infections,
tumours, autoantigens and alloantigens. Here, experimen-
tal models of disease provide greater insight into the
mechanisms that govern the development, function and
maintenance of ELFs. These studies have led to the iden-
tification of novel immune cell subsets and stromal cell
populations and new regulatory mechanisms that reflect
potential therapeutic targets for immunomodulation of
ELF activity. Significantly, molecular signatures of ELFs
also have the potential to yield biomarkers capable of
stratifying patients into defined classes of disease based
on pathology. These are likely to facilitate clinical deci-
sions regarding the most appropriate therapy for patients
with ELF-associated disease. Although experimental ani-
mal models have been the frontrunners in defining mech-
anistic aspects of ELF development, clinical studies in
human conditions have validated many of these findings
and shed light on the likely efficacy of current biologicals.
Our capacity to stratify patients for the presence of ELFs
in early disease is improving.11 The challenge is to under-
stand when and how to target drugs against these impor-
tant structures, and to adapt clinical trials in accordance
with the activities of ELFs in cancer, infection, autoim-
munity and transplantation.
Acknowledgements
GWJ and SAJ are supported by career development fel-
lowship and programme grant funding from Arthritis
Research UK (20305, 20770).
Disclosures
The authors declare no competing interests.
References
1 Drayton DL, Liao S, Mounzer RH, Ruddle NH. Lymphoid organ development: from
ontogeny to neogenesis. Nat Immunol 2006; 7:344–53.
2 Kurashima Y, Goto Y, Kiyono H. Mucosal innate immune cells regulate both gut
homeostasis and intestinal inflammation. Eur J Immunol 2013; 43:3108–15.
3 Roozendaal R, Mebius RE. Stromal cell–immune cell interactions. Annu Rev Immunol
2011; 29:23–43.
4 Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454:428–
35.
5 Buckley CD. Why does chronic inflammation persist: an unexpected role for fibrob-
lasts. Immunol Lett 2011; 138:12–4.
6 Jones SA. Directing transition from innate to acquired immunity: defining a role for
IL-6. J Immunol 2005; 175:3463–8.
7 McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev
Immunol 2007; 7:429–42.
8 Choy EH, Kavanaugh AF, Jones SA. The problem of choice: current biologic agents
and future prospects in RA. Nat Rev Rheumatol 2013; 9:154–63.
9 Dieu-Nosjean MC, Goc J, Giraldo NA, Sautes-Fridman C, Fridman WH. Tertiary lym-
phoid structures in cancer and beyond. Trends Immunol 2014; 35:571–80.
10 Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid-like structures in
infection, cancer and autoimmunity. Nat Rev Immunol 2014; 14:447–62.
11 Pitzalis C, Kelly S, Humby F. New learnings on the pathophysiology of RA from syn-
ovial biopsies. Curr Opin Rheumatol 2013; 25:334–44.
12 van de Pavert SA, Mebius RE. New insights into the development of lymphoid tissues.
Nat Rev Immunol 2010; 10:664–74.
13 Peduto L, Dulauroy S, Lochner M, Spath GF, Morales MA, Cumano A et al. Inflam-
mation recapitulates the ontogeny of lymphoid stromal cells. J Immunol 2009;
182:5789–99.
14 Vondenhoff MF, Greuter M, Goverse G, Elewaut D, Dewint P, Ware CF et al. LTbR
signaling induces cytokine expression and up-regulates lymphangiogenic factors in
lymph node anlagen. J Immunol 2009; 182:5439–45.
15 Jarjour M, Jorquera A, Mondor I, Wienert S, Narang P, Coles MC et al. Fate mapping
reveals origin and dynamics of lymph node follicular dendritic cells. J Exp Med 2014;
211:1109–22.
16 Katakai T. Marginal reticular cells: a stromal subset directly descended from the lym-
phoid tissue organizer. Front Immunol 2012; 3:200.
17 Grogan JL, Ouyang W. A role for Th17 cells in the regulation of tertiary lymphoid
follicles. Eur J Immunol 2012; 42:2255–62.
18 Rangel-Moreno J, Carragher DM, de la Luz Garcia-Hernandez M, Hwang JY, Kusser
K, Hartson L et al. The development of inducible bronchus-associated lymphoid tissue
depends on IL-17. Nat Immunol 2011; 12:639–46.
19 Peters A, Pitcher LA, Sullivan JM, Mitsdoerffer M, Acton SE, Franz B et al. Th17 cells
induce ectopic lymphoid follicles in central nervous system tissue inflammation.
Immunity 2011; 35:986–96.
20 Benezech C, Nayar S, Finney BA, Withers DR, Lowe K, Desanti GE et al. CLEC-2 is
required for development and maintenance of lymph nodes. Blood 2014; 123:3200–7.
21 Jones GW, Bombardieri M, Greenhill CJ, McLeod L, Nerviani A, Rocher-Ros V et al.
Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflam-
matory arthritis. J Exp Med 2015; 212:1793–802.
22 Canete JD, Celis R, Yeremenko N, Sanmarti R, van Duivenvoorde L, Ramirez J et al.
Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 path-
way in rheumatoid synovitis. Arthritis Res Ther 2015; 17:173.
23 Barone F, Nayar S, Campos J, Cloake T, Withers DR, Toellner KM et al. IL-22 regu-
lates lymphoid chemokine production and assembly of tertiary lymphoid organs. Proc
Natl Acad Sci USA 2015; 112:11024–9.
24 Chaitanya GV, Omura S, Sato F, Martinez NE, Minagar A, Ramanathan M et al.
Inflammation induces neuro-lymphatic protein expression in multiple sclerosis brain
neurovasculature. J Neuroinflammation 2013; 10:125.
25 Deteix C, Attuil-Audenis V, Duthey A, Patey N, McGregor B, Dubois V et al. Intra-
graft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejec-
tion. J Immunol 2010; 184:5344–51.
26 Sawa S, Cherrier M, Lochner M, Satoh-Takayama N, Fehling HJ, Langa F et al. Line-
age relationship analysis of RORct+ innate lymphoid cells. Science 2010; 330:665–9.
27 Takatori H, Kanno Y, Watford WT, Tato CM, Weiss G, Ivanov II et al. Lymphoid tis-
sue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 2009;
206:35–41.
ª 2015 The Authors. Immunology Published by John Wiley & Sons Ltd., Immunology, 147, 141–151148
G.W. Jones and S.A. Jones
28 Sonnenberg GF, Monticelli LA, Elloso MM, Fouser LA, Artis D. CD4+ lymphoid tis-
sue-inducer cells promote innate immunity in the gut. Immunity 2011; 34:122–34.
29 Kirchberger S, Royston DJ, Boulard O, Thornton E, Franchini F, Szabady RL et al.
Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a
mouse model. J Exp Med 2013; 210:917–31.
30 Artis D, Spits H. The biology of innate lymphoid cells. Nature 2015; 517:293–301.
31 Schmutz S, Bosco N, Chappaz S, Boyman O, Acha-Orbea H, Ceredig R et al. Cutting
edge: IL-7 regulates the peripheral pool of adult RORc+ lymphoid tissue inducer cells.
J Immunol 2009; 183:2217–21.
32 Meier D, Bornmann C, Chappaz S, Schmutz S, Otten LA, Ceredig R et al. Ectopic
lymphoid-organ development occurs through interleukin 7-mediated enhanced sur-
vival of lymphoid-tissue-inducer cells. Immunity 2007; 26:643–54.
33 Fleige H, Ravens S, Moschovakis GL, Bolter J, Willenzon S, Sutter G et al. IL-17-
induced CXCL12 recruits B cells and induces follicle formation in BALT in the
absence of differentiated FDCs. J Exp Med 2014; 211:643–51.
34 Breitfeld D, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M et al. Follicular B helper
T cells express CXC chemokine receptor 5, localize to B cell follicles, and support
immunoglobulin production. J Exp Med 2000; 192:1545–52.
35 Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemokine
receptor 5 expression defines follicular homing T cells with B cell helper function. J
Exp Med 2000; 192:1553–62.
36 Hirota K, Turner JE, Villa M, Duarte JH, Demengeot J, Steinmetz OM et al. Plasticity
of Th17 cells in Peyer’s patches is responsible for the induction of T cell-dependent
IgA responses. Nat Immunol 2013; 14:372–9.
37 Lu KT, Kanno Y, Cannons JL, Handon R, Bible P, Elkahloun AG et al. Functional
and epigenetic studies reveal multistep differentiation and plasticity of in vitro-gener-
ated and in vivo-derived follicular T helper cells. Immunity 2011; 35:622–32.
38 Nakayamada S, Kanno Y, Takahashi H, Jankovic D, Lu KT, Johnson TA et al. Early
Th1 cell differentiation is marked by a Tfh cell-like transition. Immunity 2011;
35:919–31.
39 Barone F, Bombardieri M, Rosado MM, Morgan PR, Challacombe SJ, De Vita S et al.
CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren’s
syndrome and MALT lymphoma: association with reactive and malignant areas of
lymphoid organization. J Immunol 2008; 180:5130–40.
40 Rangel-Moreno J, Moyron-Quiroz JE, Hartson L, Kusser K, Randall TD. Pulmonary
expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine
ligand 21 is essential for local immunity to influenza. Proc Natl Acad Sci USA 2007;
104:10577–82.
41 Sato M, Hirayama S, Matsuda Y, Wagnetz D, Hwang DM, Guan Z et al. Stromal acti-
vation and formation of lymphoid-like stroma in chronic lung allograft dysfunction.
Transplantation 2011; 91:1398–405.
42 Braun A, Takemura S, Vallejo AN, Goronzy JJ, Weyand CM. Lymphotoxin b-
mediated stimulation of synoviocytes in rheumatoid arthritis. Arthritis Rheum 2004;
50:2140–50.
43 Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O’Fallon WM et al. Lym-
phoid neogenesis in rheumatoid synovitis. J Immunol 2001; 167:1072–80.
44 Timmer TC, Baltus B, Vondenhoff M, Huizinga TW, Tak PP, Verweij CL et al.
Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues
dissected by genomics technology: identification of the interleukin-7 signaling pathway
in tissues with lymphoid neogenesis. Arthritis Rheum 2007; 56:2492–502.
45 Bombardieri M, Kam NW, Brentano F, Choi K, Filer A, Kyburz D et al. A BAFF/
APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid syn-
ovial fibroblasts to induce AID expression and Ig class-switching in B cells. Ann
Rheum Dis 2011; 70:1857–65.
46 Benezech C, White A, Mader E, Serre K, Parnell S, Pfeffer K et al. Ontogeny of stro-
mal organizer cells during lymph node development. J Immunol 2010; 184:4521–30.
47 van de Pavert SA, Olivier BJ, Goverse G, Vondenhoff MF, Greuter M, Beke P et al.
Chemokine CXCL13 is essential for lymph node initiation and is induced by retinoic
acid and neuronal stimulation. Nat Immunol 2009; 10:1193–9.
48 Luther SA, Bidgol A, Hargreaves DC, Schmidt A, Xu Y, Paniyadi J et al. Differing
activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and
dendritic cell recruitment and lymphoid neogenesis. J Immunol 2002; 169:424–33.
49 Luther SA, Lopez T, Bai W, Hanahan D, Cyster JG. BLC expression in pancreatic
islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis.
Immunity 2000; 12:471–81.
50 Ansel KM, Ngo VN, Hyman PL, Luther SA, Forster R, Sedgwick JD et al. A chemo-
kine-driven positive feedback loop organizes lymphoid follicles. Nature 2000; 406:309–
14.
51 Allen CD, Ansel KM, Low C, Lesley R, Tamamura H, Fujii N et al. Germinal center
dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol
2004; 5:943–52.
52 Luther SA, Ansel KM, Cyster JG. Overlapping roles of CXCL13, interleukin 7 receptor
a, and CCR7 ligands in lymph node development. J Exp Med 2003; 197:1191–8.
53 Ohl L, Henning G, Krautwald S, Lipp M, Hardtke S, Bernhardt G et al. Cooperating
mechanisms of CXCR5 and CCR7 in development and organization of secondary lym-
phoid organs. J Exp Med 2003; 197:1199–204.
54 Chen SC, Vassileva G, Kinsley D, Holzmann S, Manfra D, Wiekowski MT et al. Ecto-
pic expression of the murine chemokines CCL21a and CCL21b induces the formation
of lymph node-like structures in pancreas, but not skin, of transgenic mice. J Immunol
2002; 168:1001–8.
55 Fan L, Reilly CR, Luo Y, Dorf ME, Lo D. Cutting edge: ectopic expression of the che-
mokine TCA4/SLC is sufficient to trigger lymphoid neogenesis. J Immunol 2000;
164:3955–9.
56 Christopherson KW 2nd, Hood AF, Travers JB, Ramsey H, Hromas RA. Endothelial
induction of the T-cell chemokine CCL21 in T-cell autoimmune diseases. Blood 2003;
101:801–6.
57 Weninger W, Carlsen HS, Goodarzi M, Moazed F, Crowley MA, Baekkevold ES et al.
Naive T cell recruitment to nonlymphoid tissues: a role for endothelium-expressed
CC chemokine ligand 21 in autoimmune disease and lymphoid neogenesis. J Immunol
2003; 170:4638–48.
58 Baddoura FK, Nasr IW, Wrobel B, Li Q, Ruddle NH, Lakkis FG. Lymphoid neogene-
sis in murine cardiac allografts undergoing chronic rejection. Am J Transplant 2005;
5:510–6.
59 Barone F, Bombardieri M, Manzo A, Blades MC, Morgan PR, Challacombe SJ et al.
Association of CXCL13 and CCL21 expression with the progressive organization of
lymphoid-like structures in Sjogren’s syndrome. Arthritis Rheum 2005; 52:1773–84.
60 Bento DC, Jones E, Junaid S, Tull J, Williams GT, Godkin A et al. High endothelial
venules are rare in colorectal cancers but accumulate in extra-tumoral areas with dis-
ease progression. Oncoimmunology 2015; 4:e974374.
61 Canete JD, Santiago B, Cantaert T, Sanmarti R, Palacin A, Celis R et al. Ectopic lym-
phoid neogenesis in psoriatic arthritis. Ann Rheum Dis 2007; 66:720–6.
62 Cipponi A, Mercier M, Seremet T, Baurain JF, Theate I, van den Oord J et al. Neoge-
nesis of lymphoid structures and antibody responses occur in human melanoma
metastases. Cancer Res 2012; 72:3997–4007.
63 Manzo A, Bugatti S, Caporali R, Prevo R, Jackson DG, Uguccioni M et al. CCL21
expression pattern of human secondary lymphoid organ stroma is conserved in
inflammatory lesions with lymphoid neogenesis. Am J Pathol 2007; 171:1549–62.
64 Weiss JM, Cufi P, Bismuth J, Eymard B, Fadel E, Berrih-Aknin S et al. SDF-1/
CXCL12 recruits B cells and antigen-presenting cells to the thymus of autoimmune
myasthenia gravis patients. Immunobiology 2013; 218:373–81.
65 Hindley JP, Jones E, Smart K, Bridgeman H, Lauder SN, Ondondo B et al. T-cell traf-
ficking facilitated by high endothelial venules is required for tumor control after regu-
latory T-cell depletion. Cancer Res 2012; 72:5473–82.
66 Martinet L, Filleron T, Le Guellec S, Rochaix P, Garrido I, Girard JP. High endothelial
venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin
b-producing dendritic cells in human breast cancer. J Immunol 2013; 191:2001–8.
67 Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ et al. Human
solid tumors contain high endothelial venules: association with T- and B-lymphocyte
infiltration and favorable prognosis in breast cancer. Cancer Res 2011; 71:5678–87.
68 Moussion C, Girard JP. Dendritic cells control lymphocyte entry to lymph nodes
through high endothelial venules. Nature 2011; 479:542–6.
69 Onder L, Danuser R, Scandella E, Firner S, Chai Q, Hehlgans T et al. Endothelial cell-
specific lymphotoxin-beta receptor signaling is critical for lymph node and high
endothelial venule formation. J Exp Med 2013; 210:465–73.
70 Martinet L, Le Guellec S, Filleron T, Lamant L, Meyer N, Rochaix P et al. High
endothelial venules (HEVs) in human melanoma lesions: major gateways for tumor-
infiltrating lymphocytes. Oncoimmunology 2012; 1:829–39.
71 Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human
tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298–306.
72 Schrama D, Voigt H, Eggert AO, Xiang R, Zhou H, Schumacher TN et al. Immuno-
logical tumor destruction in a murine melanoma model by targeted LTa independent
of secondary lymphoid tissue. Cancer Immunol Immunother 2008; 57:85–95.
73 Schrama D, thor Straten P, Fischer WH, McLellan AD, Brocker EB, Reisfeld RA et al.
Targeting of lymphotoxin-a to the tumor elicits an efficient immune response associ-
ated with induction of peripheral lymphoid-like tissue. Immunity 2001; 14:111–21.
74 Peske JD, Thompson ED, Gemta L, Baylis RA, Fu YX, Engelhard VH. Effector lym-
phocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours
and enhanced anti-tumour immunity. Nat Commun 2015; 6:7114.
75 Lucchesi D, Bombardieri M. The role of viruses in autoreactive B cell activation
within tertiary lymphoid structures in autoimmune diseases. J Leukoc Biol 2013;
94:1191–9.
76 Neyt K, Perros F, GeurtsvanKessel CH, Hammad H, Lambrecht BN. Tertiary lym-
phoid organs in infection and autoimmunity. Trends Immunol 2012; 33:297–305.
77 Khader SA, Rangel-Moreno J, Fountain JJ, Martino CA, Reiley WW, Pearl JE et al. In
a murine tuberculosis model, the absence of homeostatic chemokines delays granu-
loma formation and protective immunity. J Immunol 2009; 183:8004–14.
ª 2015 The Authors. Immunology Published by John Wiley & Sons Ltd., Immunology, 147, 141–151 149
ELS development and role in disease
78 Mazzucchelli L, Blaser A, Kappeler A, Scharli P, Laissue JA, Baggiolini M et al. BCA-1
is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue
and gastric lymphoma. J Clin Invest 1999; 104:R49–54.
79 Slight SR, Rangel-Moreno J, Gopal R, Lin Y, Fallert Junecko BA, Mehra S et al.
CXCR5+ T helper cells mediate protective immunity against tuberculosis. J Clin Invest
2013; 123:712–26.
80 GeurtsvanKessel CH, Willart MA, Bergen IM, van Rijt LS, Muskens F, Elewaut D
et al. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the
lung of influenza virus-infected mice. J Exp Med 2009; 206:2339–49.
81 Moyron-Quiroz JE, Rangel-Moreno J, Hartson L, Kusser K, Tighe MP, Klonowski KD
et al. Persistence and responsiveness of immunologic memory in the absence of sec-
ondary lymphoid organs. Immunity 2006; 25:643–54.
82 Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, Hartson L, Sprague F, Goodrich S
et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory
immunity. Nat Med 2004; 10:927–34.
83 Sansonno D, De Vita S, Iacobelli AR, Cornacchiulo V, Boiocchi M, Dammacco F.
Clonal analysis of intrahepatic B cells from HCV-infected patients with and without
mixed cryoglobulinemia. J Immunol 1998; 160:3594–601.
84 Sansonno D, Tucci FA, Troiani L, Lauletta G, Montrone M, Conteduca V et al.
Increased serum levels of the chemokine CXCL13 and up-regulation of its gene
expression are distinctive features of HCV-related cryoglobulinemia and correlate with
active cutaneous vasculitis. Blood 2008; 112:1620–7.
85 Grewal JS, Pilgrim MJ, Grewal S, Kasman L, Werner P, Bruorton ME et al. Salivary
glands act as mucosal inductive sites via the formation of ectopic germinal centers
after site-restricted MCMV infection. FASEB J 2011; 25:1680–96.
86 Lochner M, Ohnmacht C, Presley L, Bruhns P, Si-Tahar M, Sawa S et al. Microbiota-
induced tertiary lymphoid tissues aggravate inflammatory disease in the absence of
RORct and LTi cells. J Exp Med 2011; 208:125–34.
87 Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in can-
cer treatment. Nat Rev Cancer 2012; 12:237–51.
88 Bergomas F, Grizzi F, Doni A, Pesce S, Laghi L, Allavena P et al. Tertiary intratumor
lymphoid tissue in colo-rectal cancer. Cancers (Basel) 2011; 4:1–10.
89 McMullen TP, Lai R, Dabbagh L, Wallace TM, de Gara CJ. Survival in rectal cancer is
predicted by T cell infiltration of tumour-associated lymphoid nodules. Clin Exp
Immunol 2010; 161:81–8.
90 Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A et al. CD4+ follicu-
lar helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013;
123:2873–92.
91 Nzula S, Going JJ, Stott DI. Antigen-driven clonal proliferation, somatic hypermuta-
tion, and selection of B lymphocytes infiltrating human ductal breast carcinomas.
Cancer Res 2003; 63:3275–80.
92 Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH et al. CD20+
tumor-infiltrating lymphocytes have an atypical CD27 memory phenotype and
together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Can-
cer Res 2012; 18:3281–92.
93 Willis SN, Mallozzi SS, Rodig SJ, Cronk KM, McArdel SL, Caron T et al. The
microenvironment of germ cell tumors harbors a prominent antigen-driven humoral
response. J Immunol 2009; 182:3310–7.
94 Ladanyi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A et al. Density of DC-LAMP+
mature dendritic cells in combination with activated T lymphocytes infiltrating pri-
mary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol
Immunother 2007; 56:1459–69.
95 Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V et al. Long-
term survival for patients with non-small-cell lung cancer with intratumoral lymphoid
structures. J Clin Oncol 2008; 26:4410–7.
96 Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J et al. Presence of B
cells in tertiary lymphoid structures is associated with a protective immunity in
patients with lung cancer. Am J Respir Crit Care Med 2014; 189:832–44.
97 Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S et al. Dendritic
cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune
contexture and license the positive prognostic value of infiltrating CD8+ T cells. Can-
cer Res 2014; 74:705–15.
98 Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean MC, Riquet M et al. Character-
istics and clinical impacts of the immune environments in colorectal and renal cell carci-
noma lung metastases: influence of tumor origin. Clin Cancer Res 2013; 19:4079–91.
99 Kirk CJ, Hartigan-O’Connor D, Mule JJ. The dynamics of the T-cell antitumor
response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extran-
odally. Cancer Res 2001; 61:8794–802.
100 Joshi NS, Akama-Garren EH, Lu Y, Lee DY, Chang GP, Li A et al. Regulatory T cells
in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses.
Immunity 2015; 43:579–90.
101 Klimiuk PA, Goronzy JJ, Bjornsson J, Beckenbaugh RD, Weyand CM. Tissue cytokine
patterns distinguish variants of rheumatoid synovitis. Am J Pathol 1997; 151:1311–9.
102 Manzo A, Bombardieri M, Humby F, Pitzalis C. Secondary and ectopic lymphoid tis-
sue responses in rheumatoid arthritis: from inflammation to autoimmunity and tissue
damage/remodeling. Immunol Rev 2010; 233:267–85.
103 Stott DI, Hiepe F, Hummel M, Steinhauser G, Berek C. Antigen-driven clonal prolifer-
ation of B cells within the target tissue of an autoimmune disease. The salivary glands
of patients with Sjogren’s syndrome. J Clin Invest 1998; 102:938–46.
104 Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M et al. Meningeal
B-cell follicles in secondary progressive multiple sclerosis associate with early onset of
disease and severe cortical pathology. Brain 2007; 130:1089–104.
105 Ludewig B, Odermatt B, Landmann S, Hengartner H, Zinkernagel RM. Dendritic cells
induce autoimmune diabetes and maintain disease via de novo formation of local lym-
phoid tissue. J Exp Med 1998; 188:1493–501.
106 Houtkamp MA, de Boer OJ, van der Loos CM, van der Wal AC, Becker AE. Adventi-
tial infiltrates associated with advanced atherosclerotic plaques: structural organization
suggests generation of local humoral immune responses. J Pathol 2001; 193:263–9.
107 Hu D, Mohanta SK, Yin C, Peng L, Ma Z, Srikakulapu P et al. Artery tertiary lym-
phoid organs control aorta immunity and protect against atherosclerosis via vascular
smooth muscle cell lymphotoxin b receptors. Immunity 2015; 42:1100–15.
108 Carlsen HS, Baekkevold ES, Johansen FE, Haraldsen G, Brandtzaeg P. B cell attracting
chemokine 1 (CXCL13) and its receptor CXCR5 are expressed in normal and aberrant
gut associated lymphoid tissue. Gut 2002; 51:364–71.
109 Surawicz CM, Belic L. Rectal biopsy helps to distinguish acute self-limited colitis from
idiopathic inflammatory bowel disease. Gastroenterology 1984; 86:104–13.
110 Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L et al. The nature of
small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med
2004; 350:2645–53.
111 Van Pottelberge GR, Bracke KR, Van den Broeck S, Reinartz SM, van Drunen CM,
Wouters EF et al. Plasmacytoid dendritic cells in pulmonary lymphoid follicles of
patients with COPD. Eur Respir J 2010; 36:781–91.
112 Canete JD, Celis R, Moll C, Izquierdo E, Marsal S, Sanmarti R et al. Clinical signifi-
cance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis fac-
tor a therapy in rheumatoid arthritis. Ann Rheum Dis 2009; 68:751–6.
113 Thurlings RM, Wijbrandts CA, Mebius RE, Cantaert T, Dinant HJ, van der Pouw-
Kraan TC et al. Synovial lymphoid neogenesis does not define a specific clinical
rheumatoid arthritis phenotype. Arthritis Rheum 2008; 58:1582–9.
114 Manzo A, Paoletti S, Carulli M, Blades MC, Barone F, Yanni G et al. Systematic
microanatomical analysis of CXCL13 and CCL21 in situ production and progressive
lymphoid organization in rheumatoid synovitis. Eur J Immunol 2005; 35:1347–59.
115 Shi K, Hayashida K, Kaneko M, Hashimoto J, Tomita T, Lipsky PE et al. Lymphoid
chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of
ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol
2001; 166:650–5.
116 Humby F, Bombardieri M, Manzo A, Kelly S, Blades MC, Kirkham B et al. Ectopic
lymphoid structures support ongoing production of class-switched autoantibodies in
rheumatoid synovium. PLoS Med 2009; 6:e1.
117 Rosengren S, Wei N, Kalunian KC, Zvaifler NJ, Kavanaugh A, Boyle DL. Elevated
autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and
the effect of rituximab. Arthritis Res Ther 2008; 10:R105.
118 Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in
rheumatoid synovium is B cell dependent. J Immunol 2001; 167:4710–8.
119 van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Anti-
bodies to citrullinated proteins and differences in clinical progression of rheumatoid
arthritis. Arthritis Res Ther 2005; 7:R949–58.
120 Thaunat O, Patey N, Caligiuri G, Gautreau C, Mamani-Matsuda M, Mekki Y et al.
Chronic rejection triggers the development of an aggressive intragraft immune
response through recapitulation of lymphoid organogenesis. J Immunol 2010; 185:717–
28.
121 Brown K, Sacks SH, Wong W. Tertiary lymphoid organs in renal allografts can be
associated with donor-specific tolerance rather than rejection. Eur J Immunol 2011;
41:89–96.
122 Le Texier L, Thebault P, Lavault A, Usal C, Merieau E, Quillard T et al. Long-term
allograft tolerance is characterized by the accumulation of B cells exhibiting an inhib-
ited profile. Am J Transplant 2011; 11:429–38.
123 Grabner R, Lotzer K, Dopping S, Hildner M, Radke D, Beer M et al. Lymphotoxin b
receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of
aged ApoE/ mice. J Exp Med 2009; 206:233–48.
124 Thaunat O, Patey N, Gautreau C, Lechaton S, Fremeaux-Bacchi V, Dieu-Nosjean MC
et al. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.
Transplantation 2008; 85:1648–53.
125 Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol
2015; 16:448–57.
126 Fava RA, Kennedy SM, Wood SG, Bolstad AI, Bienkowska J, Papandile A et al. Lym-
photoxin-b receptor blockade reduces CXCL13 in lacrimal glands and improves
ª 2015 The Authors. Immunology Published by John Wiley & Sons Ltd., Immunology, 147, 141–151150
G.W. Jones and S.A. Jones
corneal integrity in the NOD model of Sjogren’s syndrome. Arthritis Res Ther 2011;
13:R182.
127 Fava RA, Notidis E, Hunt J, Szanya V, Ratcliffe N, Ngam-Ek A et al. A role for the
lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis. J
Immunol 2003; 171:115–26.
128 Gatumu MK, Skarstein K, Papandile A, Browning JL, Fava RA, Bolstad AI. Blockade
of lymphotoxin-b receptor signaling reduces aspects of Sjogren’s syndrome in salivary
glands of non-obese diabetic mice. Arthritis Res Ther 2009; 11:R24.
129 Lee Y, Chin RK, Christiansen P, Sun Y, Tumanov AV, Wang J et al. Recruitment and
activation of naive T cells in the islets by lymphotoxin b receptor-dependent tertiary
lymphoid structure. Immunity 2006; 25:499–509.
130 Henry RA, Kendall PL. CXCL13 blockade disrupts B lymphocyte organization in ter-
tiary lymphoid structures without altering B cell receptor bias or preventing diabetes
in nonobese diabetic mice. J Immunol 2010; 185:1460–5.
131 Kramer JM, Klimatcheva E, Rothstein TL. CXCL13 is elevated in Sjogren’s syndrome
in mice and humans and is implicated in disease pathogenesis. J Leukoc Biol 2013;
94:1079–89.
132 Zheng B, Ozen Z, Zhang X, De Silva S, Marinova E, Guo L et al. CXCL13 neutraliza-
tion reduces the severity of collagen-induced arthritis. Arthritis Rheum 2005; 52:620–6.
133 Bucher C, Koch L, Vogtenhuber C, Goren E, Munger M, Panoskaltsis-Mortari A et al.
IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T
regulatory cell generation. Blood 2009; 114:5375–84.
134 Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K. IL-21
has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc
reduces disease progression. J Immunol 2007; 178:3822–30.
135 Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, Lowe L et al. Blockade of the
interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models
of rheumatoid arthritis. Arthritis Rheum 2007; 56:1152–63.
136 Foo SY, Zhang V, Lalwani A, Lynch JP, Zhuang A, Lam CE et al. Regulatory T cells
prevent inducible BALT formation by dampening neutrophilic inflammation. J Immu-
nol 2015; 194:4567–76.
137 Nurieva RI, Chung Y, Hwang D, Yang XO, Kang HS, Ma L et al. Generation of T fol-
licular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or
17 cell lineages. Immunity 2008; 29:138–49.
138 Goya S, Matsuoka H, Mori M, Morishita H, Kida H, Kobashi Y et al. Sustained inter-
leukin-6 signalling leads to the development of lymphoid organ-like structures in the
lung. J Pathol 2003; 200:82–7.
139 Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB et al. IL-21 initiates an alter-
native pathway to induce proinflammatory TH17 cells. Nature 2007; 448:484–7.
140 Bombardieri M, Barone F, Lucchesi D, Nayar S, van den Berg WB, Proctor G et al.
Inducible tertiary lymphoid structures, autoimmunity, and exocrine dysfunction in a
novel model of salivary gland inflammation in C57BL/6 mice. J Immunol 2012;
189:3767–76.
141 Lee JJ, McGarry MP, Farmer SC, Denzler KL, Larson KA, Carrigan PE et al. Inter-
leukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary
changes pathognomonic of asthma. J Exp Med 1997; 185:2143–56.
142 Nacionales DC, Kelly KM, Lee PY, Zhuang H, Li Y, Weinstein JS et al. Type I inter-
feron production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetra-
methyl-pentadecane (pristane). Am J Pathol 2006; 168:1227–40.
143 Ray JP, Marshall HD, Laidlaw BJ, Staron MM, Kaech SM, Craft J. Transcription factor
STAT3 and type I interferons are corepressive insulators for differentiation of follicular
helper and T helper 1 cells. Immunity 2014; 40:367–77.
144 Esen N, Rainey-Barger EK, Huber AK, Blakely PK, Irani DN. Type-I interferons sup-
press microglial production of the lymphoid chemokine, CXCL13. Glia 2014; 62:1452–
62.
145 Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD et al.
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J
Exp Med 2005; 201:233–40.
146 Batten M, Ramamoorthi N, Kljavin NM, Ma CS, Cox JH, Dengler HS et al. IL-27 sup-
ports germinal center function by enhancing IL-21 production and the function of T
follicular helper cells. J Exp Med 2010; 207:2895–906.
147 Iwasaki Y, Fujio K, Okamura T, Yanai A, Sumitomo S, Shoda H et al. Egr-2 transcrip-
tion factor is required for Blimp-1-mediated IL-10 production in IL-27-stimulated
CD4+ T cells. Eur J Immunol 2013; 43:1063–73.
148 Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, Johnson LM et al. Inter-
leukin 27 negatively regulates the development of interleukin 17-producing T helper
cells during chronic inflammation of the central nervous system. Nat Immunol 2006;
7:937–45.
149 Lee BH, Carcamo WC, Chiorini JA, Peck AB, Nguyen CQ. Gene therapy using IL-27
ameliorates Sjogren’s syndrome-like autoimmune exocrinopathy. Arthritis Res Ther
2012; 14:R172.
150 Ballesteros-Tato A, Leon B, Graf BA, Moquin A, Adams PS, Lund FE et al. Inter-
leukin-2 inhibits germinal center formation by limiting T follicular helper cell differen-
tiation. Immunity 2012; 36:847–56.
151 Johnston RJ, Choi YS, Diamond JA, Yang JA, Crotty S. STAT5 is a potent negative
regulator of TFH cell differentiation. J Exp Med 2012; 209:243–50.
152 Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z et al. Interleukin-2 sig-
naling via STAT5 constrains T helper 17 cell generation. Immunity 2007; 26:371–81.
ª 2015 The Authors. Immunology Published by John Wiley & Sons Ltd., Immunology, 147, 141–151 151
ELS development and role in disease
